Literature DB >> 2045142

Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide.

D R Singer1, N D Markandu, A L Sugden, M A Miller, G A MacGregor.   

Abstract

When the function of the renin system is inhibited, blood pressure becomes more dependent on changes in sodium and water balance. Diuretics alone and sodium restriction alone are additive to converting enzyme inhibitor therapy. However, it is not known if these two ways of reducing sodium balance are additive in the presence of established converting enzyme inhibition. We therefore performed a double-blind crossover study of the effects of moderate sodium restriction in 21 patients with essential hypertension who were already being treated with the combination of a converting enzyme inhibitor and a diuretic. After 1 month of captopril (50 mg twice daily) and hydrochlorothiazide (25 mg once daily) therapy, with their usual sodium intake, average supine blood pressure was 147/96 +/- 5/3 (SEM) mm Hg 2 hours after treatment. Patients then reduced their sodium intake to around 80-100 mmol/day for the remainder of the study. After 2 weeks of sodium restriction, they entered a double-blind, randomized, crossover study of Slow Sodium (100 mmol sodium/day) compared with Slow Sodium placebo, while continuing sodium restriction and the above treatment. During the double-blind study, after 1 month of treatment with captopril (50 mg twice daily), hydrochlorothiazide (25 mg once daily), and Slow Sodium placebo, supine blood pressure 2 hours after treatment was 138/88 +/- 4/2 mm Hg (24-hour urinary sodium 104 +/- 11 mmol). After 1 month of captopril (50 mg twice daily), hydrochlorothiazide (25 mg once daily), and Slow Sodium tablets, supine blood pressure 2 hours after treatment was 147/91 +/- 5/2 mm Hg (p less than 0.05; 24-hour urinary sodium 195 +/- 14 mmol).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2045142     DOI: 10.1161/01.hyp.17.6.798

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

Review 1.  Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.

Authors:  Samuel J Mann; Michael E Ernst
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 2.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Salt supplementation blunts the blood pressure response to telmisartan with or without hydrochlorothiazide in hypertensive patients with type 2 diabetes.

Authors:  E I Ekinci; G Thomas; R J MacIsaac; C Johnson; C Houlihan; S Panagiotopoulos; E Premaratne; H Hao; S Finch; C O'Callaghan; G Jerums
Journal:  Diabetologia       Date:  2010-04-07       Impact factor: 10.122

Review 4.  Management of Hypertension in Patients with Chronic Kidney Disease.

Authors:  Seyed Mehrdad Hamrahian
Journal:  Curr Hypertens Rep       Date:  2017-05       Impact factor: 5.369

Review 5.  Use of diuretics in cardiovascular disease: (2) hypertension.

Authors:  S U Shah; S Anjum; W A Littler
Journal:  Postgrad Med J       Date:  2004-05       Impact factor: 2.401

Review 6.  Choosing the correct drug for the individual hypertensive patient.

Authors:  L H Opie
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 7.  The effect of antihypertensive treatment on the quality of later years.

Authors:  M A James; J F Potter
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

Review 8.  Can non-pharmacological interventions reduce doses of drugs needed for the treatment of hypertension? World Hypertension League.

Authors: 
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

Review 9.  Individualised selection of antihypertensive therapy.

Authors:  L H Opie
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  New Molecules for Treating Resistant Hypertension: a Clinical Perspective.

Authors:  Omar Azzam; Marcio G Kiuchi; Jan K Ho; Vance B Matthews; Leslie Marisol Lugo Gavidia; Janis M Nolde; Revathy Carnagarin; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2019-09-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.